Transverse Medical

• ·Transverse Medical’s last known valuation is $32.0M (Aug 2023).
• ·It has raised $25.0M across 3 recorded rounds; the latest was Early Stage VC ($10.0M) in Nov 2024.
• ·Notable investors include Grant Park Ventures, Larry Lawson.
• ·Transverse Medical has filed 5 Form Ds with the SEC since 2017, most recently Dec 2024 ($10.0M sold to 2 investors).
• ·Status: Privately Held (backing).

Developer of the point-guard cerebral embolic protection technology designed to deflect, filter, capture, and remove debris during transcatheter aortic valve replacement heart procedures. The company's device has been developed to address the unmet need for full-brain protection and eliminate the clinical problem of peri procedural stroke and silent stroke in structural heart procedures and provides dynamic use of nitinol and double-edge sealing that adapts and conforms to complex arch anatomy by maintaining contact with the aorta through a proprietary Aortic-Cantilever Spring and asymmetric design which permits maximum arch vessel coverage and directs debris-laden blood through the filter, enabling physicians to have complete protection of the brain.

Sector

Healthcare

HQ

Denver, CO, United States

Founded

2011

Employees

9

Website

transversemedical.com/

Ownership

Privately Held (backing)